Abstract:Background: Pharmacogenomics (PGx) aims to utilize a patient's genetic data to enable safer and more effective prescribing of medications. The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines with strong evidence for 24 genes that affect 72 medications. Despite strong evidence linking PGx alleles to drug response, there is a large gap in the implementation and return of actionable pharmacogenetic findings to patients in standard clinical practice. In this study, we evaluated opportunities for genetically guided medication prescribing in a diverse health system and determined the frequencies of actionable PGx alleles in an ancestrally diverse biobank population. Methods: A retrospective analysis of the Penn Medicine electronic health records (EHRs), which includes ~ 3.3 million patients between 2012 and 2020, provides a snapshot of the trends in prescriptions for drugs with genotype-based prescribing guidelines ('CPIC level A or B') in the Penn Medicine health system. The Penn Medicine BioBank (PMBB) consists of a diverse group of 43,359 participants whose EHRs are linked to genome-wide SNP array and whole exome sequencing (WES) data. We used the Pharmacogenomics Clinical Annotation Tool (PharmCAT), to annotate PGx alleles from PMBB variant call format (VCF) files and identify samples with actionable PGx alleles. Results: We identified ~ 316.000 unique patients that were prescribed at least 2 drugs with CPIC Level A or B guidelines. Genetic analysis in PMBB identified that 98.9% of participants carry one or more PGx actionable alleles where treatment modification would be recommended. After linking the genetic data with prescription data from the EHR, 14.2% of participants (n = 6157) were prescribed medications that could be impacted by their genotype (as indicated by their PharmCAT report). For example, 856 participants received clopidogrel who carried CYP2C19 reduced function alleles, placing them at increased risk for major adverse cardiovascular events. When we stratified by genetic ancestry, we found disparities in PGx allele frequencies and clinical burden. Clopidogrel users of Asian ancestry in PMBB had significantly higher rates of CYP2C19 actionable alleles than European ancestry users of clopidrogrel (p < 0.0001, OR = 3.68). Conclusions: Clinically actionable PGx alleles are highly prevalent in our health system and many patients were prescribed medications that could be affected by PGx alleles. These results illustrate the potential utility of preemptive genotyping for tailoring of medications and implementation of PGx into routine clinical care.

Ethnic differences in pharmacogenomic variants: a south Asian perspective

Landscape of pharmacogenetic variants associated with non-insulin antidiabetic drugs in the Indian population

Molecular Basis of Ethnic Differences in Drug Disposition and Response

Genetic Polymorphisms And In Silico Mutagenesis Analyses Of Cyp2c9, Cyp2d6, And Cypor Genes In The Pakistani Population

Frequency of pharmacogenomic variants affecting safety and efficacy of immunomodulators and biologics in a South Asian population from Sri Lanka

The genomic landscape of CYP2D6 variation in the Indian population

Polymorphisms of ADME-related genes and their implications for drug safety and efficacy in Amazonian Amerindians

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions

Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka

The variation landscape of in a multi-ethnic Asian population

Pharmacogenomic variants affecting efficacy and toxicity of statins in a south Asian population from Sri Lanka

Genetic ancestral patterns in alleles: structural variants, rare variants, and clinical associations in 479,144 UK Biobank genomes

Pharmacogenomic profile of a central European urban random population-Czech population

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions

Genetic Literacy Series: Clinical Application Of Pharmacogenetics For Adverse Reactions To Antiepileptic Drugs An Ilae Commission Review

Pharmacogenetics of SLCO1B1: Haplotypes, Htsnps and Hepatic Expression in Three Distinct Asian Populations

Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine

Genetic Literacy Series: Clinical Application of Pharmacogenetics for Adverse Reactions to Antiepileptic Drugs

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

[Pharmacogenomics Study of 620 Whole-Exome Sequencing: Focusing on Aspirin Application].

The variation landscape of CYP2D6 in a multi-ethnic Asian population